Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With Advanced Breast Cancer
SAN ANTONIO – The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months
Source: Health News
Posted in: AICHC News
Leave a Comment (0) ↓